LY03020

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

LY03020 is a dual serotonin 5-HT 2C receptor agonist and trace amine-associated receptor 1 (TAAR1) agonist which is under development for the treatment of schizophrenia and Alzheimer's disease. It is taken orally as a controlled-release formulation. The drug is under development by Luye Pharma Group. As of February 2026, it is in phase 1 clinical trials for both indications. The chemical structure of LY03020 does not yet appear to have been disclosed.

LY03020 is a dual serotonin 5-HT 2C receptor agonist and trace amine-associated receptor 1 (TAAR1) agonist which is under development for the treatment of schizophrenia and Alzheimer's disease. It is taken orally as a controlled-release formulation. The drug is under development by Luye Pharma Group. As of February 2026, it is in phase 1 clinical trials for both indications. The chemical structure of LY03020 does not yet appear to have been disclosed.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1372022142 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

3 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.